Published in Blood on January 01, 1998
Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A (2004) 2.46
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A (2001) 2.27
Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population. J Exp Med (2002) 1.63
Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood (2001) 1.54
Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol (2013) 1.52
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica (2012) 1.45
Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am J Pathol (2003) 1.29
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene (2010) 1.25
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood (2012) 1.23
Polycomb target genes are silenced in multiple myeloma. PLoS One (2010) 1.21
Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines. Br J Haematol (2007) 1.16
G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. J Clin Invest (2007) 1.16
The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease. Immunol Rev (2003) 1.13
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol (2012) 1.12
Bone marrow injury induced via oxidative stress in mice by inhalation exposure to formaldehyde. PLoS One (2013) 1.11
Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia (2013) 1.08
Extramedullary plasmacytoma in the presence of multiple myeloma: clinical correlates and prognostic relevance. Onco Targets Ther (2012) 1.05
Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging (2006) 1.02
Hepatitis B virus infection and risk of lymphoma: results of a serological analysis within the European case-control study Epilymph. J Cancer Res Clin Oncol (2012) 1.02
Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int J Cancer (2010) 1.01
The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica (2010) 0.98
Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol (2002) 0.97
Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis (2007) 0.97
Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse. Br J Cancer (2000) 0.96
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des (2013) 0.95
Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target. Oncotarget (2016) 0.94
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res (2011) 0.93
Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother Pharmacol (2008) 0.91
Telomerase activity in plasma cell dyscrasias. Br J Cancer (2001) 0.90
Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol (2000) 0.89
Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica (2014) 0.89
Ex-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of Multiple Myeloma biology and response to therapy. PLoS One (2013) 0.89
Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol (2001) 0.88
Safety and effects of two mistletoe preparations on production of Interleukin-6 and other immune parameters - a placebo controlled clinical trial in healthy subjects. BMC Complement Altern Med (2011) 0.88
Subcutaneous plasmacytoma metastasis precipitated by tunneled central venous catheter insertion. Case Rep Oncol (2011) 0.88
Molecular aspects of multiple myeloma. Mol Pathol (2002) 0.85
Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. Am J Pathol (2001) 0.84
High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130. Clin Exp Immunol (2003) 0.82
The structure, expression and function prediction of DAZAP2, a down-regulated gene in multiple myeloma. Genomics Proteomics Bioinformatics (2004) 0.81
Translocation t(11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients: a Malaysian study. Hematol Rep (2012) 0.81
Immunophenotypic studies of monoclonal gammopathy of undetermined significance. BMC Clin Pathol (2008) 0.81
Repression of multiple myeloma growth and preservation of bone with combined radiotherapy and anti-angiogenic agent. Radiat Res (2010) 0.80
Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells. Clin Exp Immunol (1998) 0.80
Recurrent extramedullary plasmacytoma in asymptomatic multiple myeloma: a case report. J Med Case Rep (2015) 0.79
Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways. Haematologica (2009) 0.79
The effects of promoter methylation on downregulation of DAZAP2 in multiple myeloma cell lines. PLoS One (2012) 0.79
BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma. Ann Hematol (2013) 0.79
The Fascinating Effects of Baicalein on Cancer: A Review. Int J Mol Sci (2016) 0.78
Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. J Mol Diagn (2015) 0.78
Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents. J Nucl Med (2016) 0.78
Different associations of CD45 isoforms with STAT3, PKC and ERK regulate IL-6-induced proliferation in myeloma. PLoS One (2015) 0.78
N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation. Haematologica (2011) 0.78
Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis. Cell Res (2014) 0.78
Therapeutic effects of thalidomide in myeloma are associated with the expression of fibroblast growth factor receptor 3. Ther Clin Risk Manag (2005) 0.77
Adaptation to survival in germinal center is the initial step in onset of indolent stage of multiple myeloma. Mol Pharm (2011) 0.77
[Molecular pathology of plasma cell neoplasms]. Pathologe (2010) 0.77
Combined morphological and interphase fluorescence in situ hybridization study in multiple myeloma of Chinese patients. Am J Pathol (1999) 0.75
Angiogenic activity of multiple myeloma endothelial cells in vivo in the chick embryo chorioallantoic membrane assay is associated to a down-regulation in the expression of endogenous endostatin. J Cell Mol Med (2008) 0.75
IL-6 Contributes to the Defective Osteogenesis of Bone Marrow Stromal Cells from the Vertebral Body of the Glucocorticoid-Induced Osteoporotic Mouse. PLoS One (2016) 0.75
Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma. Clin Epigenetics (2017) 0.75
Multiple myeloma of the thoracic spine developed at the previous trauma site: case report. Eur Spine J (2005) 0.75
8-Chloroadenosine 3',5'-monophosphate induces cell cycle arrest and apoptosis in multiple myeloma cells through multiple mechanisms. Oncol Lett (2012) 0.75
Abnormalities in Chromosomes 1q and 13 Independently Correlate With Factors of Poor Prognosis in Multiple Myeloma. Ann Lab Med (2016) 0.75
The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution. Leukemia (2015) 0.75
Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review. Onco Targets Ther (2014) 0.75
Cancer cytogenetics: methodology revisited. Ann Lab Med (2014) 0.75
Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma. Biomed Res Int (2015) 0.75
NF-Kβ Activation in U266 Cells on Mesenchymal Stem Cells. Adv Pharm Bull (2016) 0.75
Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity. Appl Clin Genet (2010) 0.75
The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease. PLoS One (2016) 0.75
Solitary extraosseous plasmacytoma. Clin Case Rep (2016) 0.75
Increased frequency of Mediterranean fever gene variants in multiple myeloma. Oncol Lett (2014) 0.75
EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency. PLoS Biol (2017) 0.75
Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (1994) 26.02
Signal transduction by receptors with tyrosine kinase activity. Cell (1990) 22.72
ras genes. Annu Rev Biochem (1987) 22.59
The Fas death factor. Science (1995) 13.81
Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science (1994) 11.33
The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell (1992) 8.20
Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature (1986) 7.73
The CD40 antigen and its ligand. Annu Rev Immunol (1994) 7.26
Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature (1993) 7.20
The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature (1993) 7.11
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell (1992) 6.86
Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science (1997) 6.75
The biology of interleukin-6. Blood (1989) 6.65
cPLA2 is phosphorylated and activated by MAP kinase. Cell (1993) 6.61
The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell (1989) 6.43
Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature (1993) 6.38
Signal transduction via the MAP kinases: proceed at your own RSK. Proc Natl Acad Sci U S A (1993) 6.19
STATs: signal transducers and activators of transcription. Cell (1996) 6.10
Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science (1992) 6.09
Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell (1994) 5.96
The human hematopoietic colony-stimulating factors. Science (1987) 5.86
Tumor suppressor genes. Science (1991) 5.72
Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science (1992) 5.71
Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell (1993) 5.66
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (1988) 5.60
Proteins of transcription factor ISGF-3: one gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha. Proc Natl Acad Sci U S A (1992) 5.50
Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature (1992) 5.47
Biological and clinical aspects of interleukin 6. Immunol Today (1990) 5.17
Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J (1990) 5.16
Cytokine signal transduction. Cell (1994) 5.14
Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood (1996) 5.13
Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. Science (1993) 5.02
The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem Sci (1993) 4.62
Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res (1996) 4.48
The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells. Nature (1989) 4.43
Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science (1994) 4.24
Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science (1997) 4.23
Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood (1992) 4.14
Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science (1994) 4.07
Interleukin-6 in biology and medicine. Adv Immunol (1993) 4.06
Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature (1994) 4.04
Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science (1986) 3.92
The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction. Proc Natl Acad Sci U S A (1992) 3.74
vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J (1989) 3.67
Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci U S A (1993) 3.59
Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci (1994) 3.36
Cytokine receptors and signal transduction. Annu Rev Immunol (1992) 3.27
A new cytokine receptor superfamily. Trends Biochem Sci (1990) 3.24
IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science (1993) 3.13
The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science (1993) 3.12
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet (1997) 3.11
Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med (1994) 3.11
c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. EMBO J (1994) 3.01
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood (1996) 2.98
Product of vav proto-oncogene defines a new class of tyrosine protein kinase substrates. Nature (1992) 2.97
Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet (1995) 2.93
Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet (1996) 2.87
Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev (1996) 2.81
Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood (1989) 2.78
Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet (1995) 2.51
Regulators of cell death. Trends Genet (1995) 2.37
The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today (1994) 2.36
Phenotypic difference of normal plasma cells from mature myeloma cells. Blood (1993) 2.35
Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death. Curr Opin Genet Dev (1994) 2.29
Hemopoietic cell growth factors and their receptors. Annu Rev Biochem (1989) 2.28
Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet (1995) 2.26
Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood (1996) 2.21
How receptor tyrosine kinases activate Ras. Trends Biochem Sci (1993) 2.19
The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol (1992) 2.17
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci U S A (1996) 2.15
Binding of the Ras activator son of sevenless to insulin receptor substrate-1 signaling complexes. Science (1993) 2.14
Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood (1994) 2.10
Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood (1993) 2.02
Interleukin-6 in human multiple myeloma. Blood (1995) 1.95
Multiple myeloma. N Engl J Med (1997) 1.94
Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J (1994) 1.94
Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J (1995) 1.94
CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation. Immunol Today (1992) 1.93
Shc proteins are phosphorylated and regulated by the v-Src and v-Fps protein-tyrosine kinases. Proc Natl Acad Sci U S A (1992) 1.93
Cyclin D and oncogenesis. Curr Opin Genet Dev (1993) 1.88
Plasmacytomagenesis in mice: model of neoplastic development dependent upon chromosomal translocations. Carcinogenesis (1992) 1.88
A complex of Grb2 adaptor protein, Sos exchange factor, and a 36-kDa membrane-bound tyrosine phosphoprotein is implicated in ras activation in T cells. J Biol Chem (1994) 1.87
Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res (1993) 1.77
Regulators and effectors of ras proteins. Annu Rev Cell Biol (1991) 1.76
Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood (1990) 1.76
Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood (1990) 1.75
Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130. Proc Natl Acad Sci U S A (1994) 1.74
Tyrosine phosphorylation of the vav proto-oncogene product in activated B cells. Science (1992) 1.73
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood (1991) 1.73
Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest (1989) 1.72
IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol (1997) 1.68
The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood (1985) 1.67
Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. Annu Rev Immunol (1992) 1.66
Erks: their fifteen minutes has arrived. Cell Growth Differ (1992) 1.64
Fas and Fas ligand: a death factor and its receptor. Adv Immunol (1994) 1.63
Apoptosis meets signal transduction: elimination of a BAD influence. Cell (1996) 1.63
Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J (1996) 1.61
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res (2001) 6.93
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med (1989) 6.66
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 4.76
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 4.37
Single neurons in prefrontal cortex encode abstract rules. Nature (2001) 4.05
The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood (1998) 3.69
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet (1997) 3.11
B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol (1983) 3.09
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood (1996) 2.98
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A (2000) 2.81
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood (1984) 2.74
Genetic aberrations and survival in plasma cell leukemia. Leukemia (2008) 2.69
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood (2001) 2.48
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene (2001) 2.39
Hypotensive reactions: a previously uncharacterized complication of platelet transfusion? Transfusion (1996) 2.37
Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood (1998) 2.36
Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 2.33
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (2001) 2.30
Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia (2008) 2.29
Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood (1996) 2.21
Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol (2007) 2.14
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia (2011) 2.12
WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res (2001) 2.12
Benzene and multiple myeloma: appraisal of the scientific evidence. Blood (1999) 2.05
The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene (2001) 2.04
Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood (1993) 2.02
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia (2009) 1.97
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene (2006) 1.89
Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia (2009) 1.84
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia (2006) 1.79
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia (2010) 1.77
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia (2006) 1.71
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol (1997) 1.68
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia (2007) 1.66
High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol (1998) 1.61
History of the development of arsenic derivatives in cancer therapy. Oncologist (2001) 1.61
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood (2001) 1.59
Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood (1994) 1.59
Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant (2000) 1.57
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood (2001) 1.57
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia (2008) 1.56
Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia (2012) 1.54
Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood (1998) 1.52
B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation. J Clin Invest (1984) 1.51
A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene (2007) 1.46
Brief report: graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors. N Engl J Med (1993) 1.46
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia (2008) 1.46
Posttransfusion graft-versus-host disease in Japanese newborns. Transfusion (1996) 1.44
Leukocyte reduction in blood component therapy. Ann Intern Med (1992) 1.44
A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy. Leukemia (2008) 1.43
The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood (1997) 1.42
Antigens on human plasma cells identified by monoclonal antibodies. J Immunol (1983) 1.41
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis (2012) 1.40
Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia (2006) 1.39
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia (2011) 1.38
Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood (1997) 1.37
Low sensitivity of ELISA testing in early HIV infection. N Engl J Med (1986) 1.37
Studies of in vitro activation and differentiation of human B lymphocytes. I. Phenotypic and functional characterization of the B cell population responding to anti-Ig antibody. J Immunol (1985) 1.35
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets (2011) 1.33
SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem (2000) 1.31
The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia (2009) 1.30
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia (2009) 1.29
A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer (2006) 1.25
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene (2010) 1.25
Mechanical properties of the colon: comparison of the features of the African and European colon in vitro. Gut (1985) 1.24
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia (2008) 1.24
Pneumococci relatively resistant to penicillin: a prevalence survey in children. J Pediatr (1980) 1.22
Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol (2001) 1.22
Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood (1999) 1.21
Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood (2000) 1.21
Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia (2013) 1.21
Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia. J Clin Invest (1982) 1.21
Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol (2005) 1.20
Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature. Leukemia (2007) 1.18
Bortezomib as an antitumor agent. Curr Pharm Biotechnol (2006) 1.17
The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood (2001) 1.17
Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol Cell (1999) 1.16
Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J Biol Chem (2001) 1.16
A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia (2011) 1.16
Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood (1999) 1.15
Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis. Leukemia (2002) 1.15
Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother (2001) 1.15
Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood (2001) 1.15
Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol (2004) 1.14
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia (2010) 1.12
Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood (1996) 1.11
CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood (1995) 1.11
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia (2008) 1.10
MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood (1997) 1.10
Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am (1997) 1.09
Characterization of adhesion molecules on human myeloma cell lines. Blood (1992) 1.09